Literature DB >> 16283151

[Medication treatment for Parkinson's disease].

H Reichmann1.   

Abstract

In general, therapy for Parkinson's disease is dominated by dopamine agonists (DA) in younger patients and levodopa in older patients with comorbidities. Single or combined treatment with DA should be used as long as possible to avoid levodopa and associated complications. About 30% of our patients respond to DA monotherapy and tolerate it for quite a long time. It is important to sustain patient confidence. Although parkinsonism is an insidious disease of unknown cause resulting in destruction of important dopaminergic neurons, no other neurodegenerative disease can be treated as successfully.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16283151     DOI: 10.1007/s00115-005-2009-3

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  40 in total

1.  Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.

Authors:  L V Metman; M Gillespie; C Farmer; F Bibbiani; S Konitsiotis; M Morris; H Shill; W Bara-Jimenez; M M Mouradian; T N Chase
Journal:  Clin Neuropharmacol       Date:  2001 May-Jun       Impact factor: 1.592

2.  Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.

Authors:  L V Metman; P Del Dotto; K LePoole; S Konitsiotis; J Fang; T N Chase
Journal:  Arch Neurol       Date:  1999-11

3.  A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

Authors: 
Journal:  Arch Neurol       Date:  2002-12

4.  Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).

Authors:  C Warren Olanow; Philippe Damier; Christopher G Goetz; Thomas Mueller; John Nutt; Olivier Rascol; Alexandru Serbanescu; Frieda Deckers; Hermann Russ
Journal:  Clin Neuropharmacol       Date:  2004 Mar-Apr       Impact factor: 1.592

5.  Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.

Authors:  Guy Van Camp; Anja Flamez; Bernard Cosyns; Caroline Weytjens; Luc Muyldermans; Michel Van Zandijcke; Johan De Sutter; Patrick Santens; Pierre Decoodt; Christian Moerman; Danny Schoors
Journal:  Lancet       Date:  2004-04-10       Impact factor: 79.321

6.  Where does parkinson disease pathology begin in the brain?

Authors:  Kelly Del Tredici; Udo Rüb; Rob A I De Vos; Jürgen R E Bohl; Heiko Braak
Journal:  J Neuropathol Exp Neurol       Date:  2002-05       Impact factor: 3.685

7.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

8.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

Authors: 
Journal:  JAMA       Date:  2000-10-18       Impact factor: 56.272

9.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Authors:  Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

10.  Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease.

Authors:  V Kostic; S Przedborski; E Flaster; N Sternic
Journal:  Neurology       Date:  1991-02       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.